Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies
- PMID: 36634434
- DOI: 10.1016/j.ctrv.2023.102510
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies
Abstract
The indolent B-cell non-Hodgkin lymphomas (B-NHL) comprise a heterogenous group of lymphoproliferative disorders characterized by slow growth kinetics and a relapsing/remitting course. Management has, until recently, been uniform across all indolent B-NHL subtypes. Improving insight into pathophysiological and molecular features of each disease has led to development of several targeted therapies. Consequently, each subtype must now be considered an individual entity. In this review, we consider the three commonest indolent B-NHLs: follicular lymphoma, marginal zone lymphoma and Waldenstrom's macroglobulinemia and review in detail the data on approved and emerging targeted therapeutic agents for each B-NHL subtype.
Keywords: Follicular lymphoma; Marginal zone lymphoma; Targeted therapies; Waldenstrom’s macroglobulinemia.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Elizabeth Smyth: Travel/ Accommodation / Expenses: Amgen Astellas BioPharma. Chan Y. Cheah: Consulting/advisory/honoraria – Roche, Janssen, MSD, Gilead, AstraZeneca, Lilly, TG therapeutics, Beigene, Novartis, BMS; research funding – BMS, Roche, Abbvie; MSD. John F. Seymour: research funding Abbvie, BMS, Roche; advisory board/honoraria Abbie, Astra Zeneca, Beigene, BMS, Genentech, Genor Bio, Gilead, Janssen, Roche, Sunesis, TG Therapeutics
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
